Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2CNS 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Breast 1

Conditions

Wilms Tumor 6Osteosarcoma 6Neuroblastoma 6Leukemia, Myeloid, Acute 6Glioma 6Rhabdoid Tumor 5Neoplasm Metastasis 5Lymphoma, Non-Hodgkin 5Hepatoblastoma 5Sarcoma 4Rhabdomyosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Multiple Myeloma 4Medulloblastoma 4Histiocytosis, Langerhans-Cell 4Ependymoma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Sarcoma, Ewing 3Prostatic Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma 3Lung Neoplasms 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mouth Neoplasms 2Melanoma 2

Interventions

pembrolizumab 19Nivolumab 18Specimen Handling 16Magnetic Resonance Spectroscopy 12Ipilimumab 11Biopsy 6relatlimab 4Opdualag 4CTLA-4 Antigen 4trametinib 3dabrafenib 3binimetinib 3aldesleukin 3Cyclophosphamide 3omipalisib 2fludarabine 2capivasertib 2atezolizumab 2X-Rays 2Taxes 2Surveys and Questionnaires 2Standard of Care 2Radiosurgery 2Radiation 2Practice Guidelines as Topic 2Pemetrexed 2Paclitaxel 2Methods 2Introns 2Interferon alpha-2 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × X-Rays × 30 days × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡